Lawsuit claims Sanofi dragged its feet on Lemtrada OK to avoid rights payoff

Sanofi ($SNY) is accused of stalling its multiple sclerosis drug Lemtrada to avoid paying out $708 million to rights holders as required by its 2011 deal to buy Genzyme. As part of that deal, the French drugmaker agreed to a series of milestone payments, including an FDA approval deadline for Lemtrada. A lawsuit filed on behalf of rights holders claims Sanofi deliberately filed a substandard approval application to delay the FDA nod. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.